Reported Earnings • Apr 15
Second quarter 2026 earnings released: CA$0.018 loss per share (vs CA$0.013 loss in 2Q 2025) Second quarter 2026 results: CA$0.018 loss per share (further deteriorated from CA$0.013 loss in 2Q 2025). Revenue: CA$1.64m (up 64% from 2Q 2025). Net loss: CA$1.47m (loss widened 105% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. Announcement • Apr 07
Telescope Innovations Corp., Annual General Meeting, Jun 15, 2026 Telescope Innovations Corp., Annual General Meeting, Jun 15, 2026. New Risk • Mar 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$6.1m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Revenue is less than US$5m (CA$6.3m revenue, or US$4.5m). Market cap is less than US$100m (CA$31.5m market cap, or US$22.7m). Reported Earnings • Jan 29
First quarter 2026 earnings released: CA$0.021 loss per share (vs CA$0.006 loss in 1Q 2025) First quarter 2026 results: CA$0.021 loss per share (further deteriorated from CA$0.006 loss in 1Q 2025). Revenue: CA$2.70m (up 124% from 1Q 2025). Net loss: CA$1.22m (loss widened 254% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jan 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 16% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (CA$4.8m revenue, or US$3.5m). Market cap is less than US$100m (CA$42.6m market cap, or US$31.0m). Reported Earnings • Dec 25
Full year 2025 earnings released: CA$0.029 loss per share (vs CA$0.025 loss in FY 2024) Full year 2025 results: CA$0.029 loss per share (further deteriorated from CA$0.025 loss in FY 2024). Revenue: CA$5.78m (up 31% from FY 2024). Net loss: CA$1.56m (loss widened 18% from FY 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Oct 15
Telescope Innovations Corp. announced that it has received CAD 6.5 million in funding On October 14, 2025, the Telescope Innovations Corp closed the transaction by issuing 5,186,816 common shares of the company at a price CAD 0.25 for the proceeds of CAD 1,296,704 in second and final tranche. A finder’s fee in the amount of CAD 3,500 has been paid by the Company. New Risk • Sep 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Revenue is less than US$5m (CA$4.6m revenue, or US$3.4m). Market cap is less than US$100m (CA$25.7m market cap, or US$18.7m). Reported Earnings • Jul 17
Third quarter 2025 earnings released: CA$0.009 loss per share (vs CA$0.004 loss in 3Q 2024) Third quarter 2025 results: CA$0.009 loss per share (further deteriorated from CA$0.004 loss in 3Q 2024). Revenue: CA$1.39m (up 14% from 3Q 2024). Net loss: CA$501.5k (loss widened 150% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Jul 04
Telescope Innovations Corp. announced that it expects to receive CAD 5 million in funding Telescope Innovations Corp announced a non-brokered private placement of 20,000,000 shares at issue price CAD 0.25 per share for gross proceeds CAD 5,000,000 on July 3, 2025. The transaction is subject to compliance with applicable regulatory requirements New Risk • Jun 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Revenue is less than US$5m (CA$4.4m revenue, or US$3.2m). Market cap is less than US$100m (CA$22.0m market cap, or US$16.1m). Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. CEO & Chairman of Board Henry Dubina was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Apr 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.1m (US$9.49m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$13.1m market cap, or US$9.49m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$4.4m revenue, or US$3.2m). Reported Earnings • Apr 25
Second quarter 2025 earnings released: CA$0.013 loss per share (vs CA$0.01 loss in 2Q 2024) Second quarter 2025 results: CA$0.013 loss per share (further deteriorated from CA$0.01 loss in 2Q 2024). Revenue: CA$1.00m (up 46% from 2Q 2024). Net loss: CA$713.3k (loss widened 32% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Apr 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (CA$4.1m revenue, or US$3.0m). Market cap is less than US$100m (CA$14.0m market cap, or US$10.1m). Announcement • Feb 24
Telescope Innovations Corp., Annual General Meeting, Apr 23, 2025 Telescope Innovations Corp., Annual General Meeting, Apr 23, 2025. Announcement • Feb 05
Telescope Innovations Corp. announced that it expects to receive CAD 3 million in funding Telescope Innovations Corp. announced a non-brokered private placement of 7,500,000 units at a price of CAD 0.40 per unit for the gross proceeds of CAD 3,000,000 on February 4, 2025. Each unit will consist of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to purchase an additional common share at a price of CAD 0.75 for a period of thirty-six months. In connection with closing of the Offering, the Company may pay finders’ fees to eligible parties who have assisted in introducing subscribers to the Offering. Completion of the Offering remains subject to regulatory approval. Reported Earnings • Jan 28
First quarter 2025 earnings released: CA$0.006 loss per share (vs CA$0.004 profit in 1Q 2024) First quarter 2025 results: CA$0.006 loss per share (down from CA$0.004 profit in 1Q 2024). Revenue: CA$1.20m (down 20% from 1Q 2024). Net loss: CA$343.5k (down 260% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Jan 16
Telescope Innovations Corp. Announces the Successful Outcomes of Its Brine-To-Battery Program Telescope Innovations Corp. announced the successful outcomes of its Brine-to-Battery Program. Over the past year, Telescope Innovations' proprietary ReCRFTTM recrystallization technology has produced battery-grade (>99% pure) lithium carbonate from a wide variety of North American lithium-containing brines. Direct Lithium Extraction (DLE) eluates were obtained from various producers with lithium brine projects across Canada and the US. Isolating dilute lithium from low-grade brine resources in North America traditionally requires several processing steps and additional reagents, resulting in prohibitive CAPEX and OPEX costs relative to overseas operations. Telescope Innovations' ReCRFTTM collapses the lithium carbonate refining flow sheet, reducing these costs to enable a sustainable, on-shore supply of battery raw materials. ReCRFTTM advantages include: 1. Elimination of polishing steps: Lithium carbonate can be produced directly from DLE concentrates, without traditional feed polishing steps. This reduces reagent, plant equipment, energy, and operating costs. A high tolerance for feed variability: Through the Company's Brine-to-Battery program, ReCRFTTM has demonstrated the production of >99% pure lithium carbonate from eight brine sources, originating from Alberta, Texas, Nevada, and Arkansas, and ranging in original lithium purity from 15% - 93% (Figure 1, bottom). Telescope Innovations has protected ReCRFTTM technology through a patent application under the Patent Cooperation Treaty and additional jurisdictions. Reported Earnings • Dec 26
Full year 2024 earnings released: CA$0.025 loss per share (vs CA$0.014 loss in FY 2023) Full year 2024 results: CA$0.025 loss per share (further deteriorated from CA$0.014 loss in FY 2023). Revenue: CA$4.43m (up 57% from FY 2023). Net loss: CA$1.32m (loss widened 84% from FY 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 12
Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.001 profit in 3Q 2023) Third quarter 2024 results: CA$0.004 loss per share (down from CA$0.001 profit in 3Q 2023). Revenue: CA$1.22m (up 21% from 3Q 2023). Net loss: CA$200.3k (down 395% from profit in 3Q 2023). Reported Earnings • Apr 19
Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0 in 2Q 2023) Second quarter 2024 results: CA$0.01 loss per share (further deteriorated from CA$0 in 2Q 2023). Revenue: CA$686.2k (down 16% from 2Q 2023). Net loss: CA$541.2k (down CA$552.5k from profit in 2Q 2023). Announcement • Feb 13
Telescope Innovations Corp., Annual General Meeting, Apr 18, 2024 Telescope Innovations Corp., Annual General Meeting, Apr 18, 2024. Reported Earnings • Jan 30
First quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 1Q 2023) First quarter 2024 results: EPS: CA$0.004 (up from CA$0.006 loss in 1Q 2023). Revenue: CA$1.50m (up 195% from 1Q 2023). Net income: CA$215.0k (up CA$485.2k from 1Q 2023). Profit margin: 14% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Announcement • Jan 24
Telescope Innovations Corp. Files Provisional Patent Application Telescope Innovations Corp. announced it has filed a provisional patent application (63/606,069) on a disruptive new technique to purify lithium carbonate, a critical mineral building block for lithium ion battery production and particularly for low-cost LFP battery chemistries. This is Telescope's second application related to processing battery raw materials, the first of which provides a low-temperature method for generating lithium sulfide. The current provisional application describes a single-step process that produces battery-grade, >99.9% lithium carbonate from crude material of 20-95% purity. This technology can dramatically reduce the requirement for pre-processing of crude lithium brine feeds, which conventionally accounts for up to 80% of refinement costs. New Risk • Jul 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (CA$9.66m market cap, or US$7.29m). Minor Risks Shareholders have been diluted in the past year (10% increase in shares outstanding). Revenue is less than US$5m (CA$2.9m revenue, or US$2.2m). Board Change • Feb 08
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Andy Robinson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Dec 30
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Andy Robinson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Dec 12
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Andy Robinson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Andy Robinson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Nov 11
Telescope Innovations Corp. announced that it has received CAD 1.46385 million in funding from New Age Ventures and other investors Telescope Innovations Corp. announced a non-brokered private placement of a total of 4,879,499 units at a price of CAD 0.30 per unit for aggregate gross proceeds of CAD 1,463,849 led by new investor New Age Ventures on November 10, 2022. Each unit consists of one common share and one-half-of-one common share purchase warrant. Each warrant entitles the holder thereof to purchase one additional common share of the Issuer at a price of CAD 0.75 per warrant share until November 10, 2024, subject to accelerated expiry at the option of the company in the event the closing price of the shares on the Canadian Securities Exchange is CAD 1.00 or more for ten consecutive trading days. The Units were offered pursuant to exemptions from the registration and prospectus requirements of applicable securities legislation. The securities are subject to restrictions on resale in accordance with applicable securities laws until March 11, 2023. The company didn't pay any finders' fees or commissions in the transaction. The transaction included participation from insiders of the company who subscribed for an aggregate of 1,160,332 units as well new and existing shareholders. Announcement • Sep 07
Telescope Innovations Corp. Appoints Dr. Jeffrey Sherman as Chief Operating Officer Telescope Innovations Corp. announced that Dr. Jeffrey Sherman has accepted the position of Chief Operating Officer of the Company. Jeff brings over thirty years of experience in the scientific instrument industry. He has worked with emerging technology startups, mid-sized companies, and internationally leading suppliers of lab technology including Micromeritics Instrument Corporation, ThermoFisher Scientific, and Mettler-Toledo. Jeff's breadth of experience covers technical scientific roles, global sales management, and general management. He has also been intimately involved with strategy development, mergers, acquisitions, technology licensing, divestitures, and business consolidations. His successful market and business development track record has served both industrial and academic clients engaged in new entity discovery, process and product development, and scale-up and manufacturing in the bio- pharmaceutical, fine chemical, oil and gas, polymer and plastics, and mining sectors. Board Change • Aug 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director James Robinson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Aug 11
Telescope Innovations Corp. Completes Feasibility Research Project Telescope Innovations Corp. announces that it has completed a four-month feasibility project funded by Pfizer to explore the acceleration of pharmaceutical process development through the use of automation. To successfully complete this project, Telescope created a proof-of- concept robotic workflow leveraging its proprietary in-situ analytical technology and automation tools and examined how the proof-of-concept platform could evolve over the next decade. The envisioned application of the platform is to help accelerate the translation of newly identified chemistry, processes, and materials from initial discovery to scaled-up commercial deployment. Announcement • Jun 29
Telescope Innovations Corp. Launches First Automation Product Telescope Innovations Corp. announced the creation of "Telescope Automation", a division of the Company that develops automated systems to accelerate chemical and biopharmaceutical research and development. Telescope Automation announced to launch its first product, the Direct Inject Liquid Chromatography platform, an innovative instrument for real-time, immediate analysis of chemical reactions. The DILC platform fuses Telescope's proprietary hardware, software, and unique integration know-how with proven sampling technology supplied by an internationally renowned manufacturer of lab instrumentation (the "Sampler Manufacturer"). This product launch enables Telescope to capture the fast-developing market opportunity for the DILC system, generate revenue, and establish the Company as a partner of choice for process laboratory tool integration. The commercial deployment and insight provided by DILC technology will highlight, at an industrial scale, the unique combination of skills Telescope provides to support chemical, biopharmaceutical, and manufacturing process development. The DILC platform enables rapid, robust online analysis of chemical reactions. Specifically, the system samples batch or continuous processes and automatically quenches, dilutes, and injects the samples into a high- or ultra-performance liquid chromatography ("HPLC" or "UPLC") instrument. When combined with orthogonal techniques such as spectroscopic analysis, this system provides full, comprehensive profiles of chemical reactions in real time. The DILC system is fully automated and uses the market leading in-situ sampling probe (sold by the Sampler Manufacturer) to deliver reaction samples to HPLC/UPLC instruments in pseudo-real time. The entire process is controlled through Telescope's intuitive software for workflow management. The DILC system ensures precise and reproducible samples, especially in heterogeneous and multiphase reactions or reactions at sub-ambient or elevated temperatures and pressures. Furthermore, the DILC system eliminates delays in quenching that typically lead to variable results and inaccurate analytical information. Announcement • Feb 19
Telescope Innovations Corp., Annual General Meeting, Apr 21, 2022 Telescope Innovations Corp., Annual General Meeting, Apr 21, 2022. Announcement • Jan 18
Telescope Innovations Corp. Files Patent Cooperation Treaty Application on Scalable Psilocybin and Tryptamine Synthesis Telescope Innovations Corp. announced that it has filed a Patent Cooperation Treaty (PCT) patent application for its scalable manufacturing methods to produce psilocybin and related tryptamine compounds. This application claims the priority date of a preceding provisional application filed with the United States Patent and Trade Office on December 31, 2020. This PCT filing covers novel synthetic routes for the production of psilocybin and psilocin along with their precursors, analogs, and derivatives. These molecules belong to the tryptamine class of compounds that has been gaining momentum in the psychedelic medicine space in recent years. The processes outlined in this patent application are positioned to enable scalable manufacturing because they require fewer synthetic steps than current methods, utilize cost effective and readily available starting materials, and leverage chemical manufacturing processes that are already standard practice in the pharmaceutical industry. Telescope's synthetic methods are therefore well-poised for compatibility with the standards of current Good Manufacturing Practices (cGMP) ultimately required for pharmaceutical deployment. The synthetic processes described in the PCT application are not limited to the production of psilocybin, but enable access to a wide variety of tryptamines and can be easily adapted to produce specific derivatives. Derivatives are currently being explored by drug development companies seeking to tune the predictability, potency, or pharmacokinetic profiles of psychedelic therapeutics. Telescope's intellectual property portfolio is therefore flexible and amenable to changing demands as different molecules are targeted throughout pharmaceutical development in the psychedelic space. Indeed, while developing proprietary synthesis processes, Telescope has discovered new molecules (Novel Chemical Entities; "NCEs") that may become candidates for preclinical development. These NCEs are also captured within the PCT application. Board Change • Oct 06
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
